JP2024520020A5 - - Google Patents

Info

Publication number
JP2024520020A5
JP2024520020A5 JP2023572876A JP2023572876A JP2024520020A5 JP 2024520020 A5 JP2024520020 A5 JP 2024520020A5 JP 2023572876 A JP2023572876 A JP 2023572876A JP 2023572876 A JP2023572876 A JP 2023572876A JP 2024520020 A5 JP2024520020 A5 JP 2024520020A5
Authority
JP
Japan
Prior art keywords
patient
score
nash
nash crn
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/054867 external-priority patent/WO2022249071A1/en
Publication of JP2024520020A publication Critical patent/JP2024520020A/ja
Publication of JP2024520020A5 publication Critical patent/JP2024520020A5/ja
Pending legal-status Critical Current

Links

JP2023572876A 2021-05-27 2022-05-25 肝疾患の治療における使用のためのペマフィブラートおよび／またはトホグリフロジン Pending JP2024520020A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194088P 2021-05-27 2021-05-27
US63/194,088 2021-05-27
PCT/IB2022/054867 WO2022249071A1 (en) 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease

Publications (2)

Publication Number Publication Date
JP2024520020A JP2024520020A (ja) 2024-05-21
JP2024520020A5 true JP2024520020A5 (https=) 2025-05-08

Family

ID=82020168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572876A Pending JP2024520020A (ja) 2021-05-27 2022-05-25 肝疾患の治療における使用のためのペマフィブラートおよび／またはトホグリフロジン

Country Status (10)

Country Link
US (1) US20240277745A1 (https=)
EP (1) EP4346809A1 (https=)
JP (1) JP2024520020A (https=)
KR (1) KR20240013203A (https=)
CN (1) CN117677385A (https=)
AU (1) AU2022282651A1 (https=)
BR (1) BR112023024701A2 (https=)
CA (1) CA3221073A1 (https=)
MX (1) MX2023013886A (https=)
WO (1) WO2022249071A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250034041A (ko) * 2022-07-15 2025-03-10 교와 가부시키가이샤 혈중 ldl 콜레스테롤 저하제
CN115991682A (zh) * 2023-03-21 2023-04-21 广州佳途科技股份有限公司 一种培马贝特-d4的制备方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI696462B (zh) 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
ES3026786T3 (en) 2017-01-11 2025-06-12 Kowa Co Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease

Similar Documents

Publication Publication Date Title
JP6250588B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
JP5869469B2 (ja) 鉄が病因に関与する肝臓疾患の処置
JP2018507914A5 (https=)
KR102876077B1 (ko) 간 질환을 치료하기 위한 병용 요법
JP2019534311A (ja) 線維症の治療
KR102000332B1 (ko) 간내 담즙정체성 질환의 치료
JP7617898B2 (ja) Ｅｙｐ００１を使用した改善された処置
JP2024520020A5 (https=)
CN113301889A (zh) Nafld和nash的联合治疗
US20210260025A1 (en) Capsid assembly modulator dosing regimen
JP2024524273A5 (https=)
JP2024502673A (ja) Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
WO2019024758A1 (zh) 一种糖苷类化合物在制备用于治疗肝纤维化药物中的应用
JP2023516505A (ja) 非アルコール性脂肪性肝炎の治療のためのセマグルチド
JP2020504129A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法
JP2024500324A5 (https=)
JP2001520994A (ja) 消化管疾患を治療するためにクマリン誘導体を用いる用途
JP2002524417A5 (https=)
JP2023541170A5 (https=)
JP2022527190A5 (https=)
JP3885135B2 (ja) Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
CN113015525A (zh) 依达拉奉在非酒精性脂肪肝炎治疗或预防中的应用
AU2019276955A1 (en) Combinations comprising tropifexor and cenicriviroc
CN111084808A (zh) 咳特灵制剂在治疗乙型肝炎中的应用
JP2023543131A5 (https=)